Trump Administration Claims New Drug Price Deals Could Save $529 Billion

What Happened?

The Trump administration announced new agreements with 17 pharmaceutical companies that it says could lower prescription drug costs in the United States over the next 10 years. According to White House estimates, the deals would save consumers and federal health programs roughly $529 billion if the pricing structure is fully implemented.

The plan centers on tying certain U.S. drug prices more closely to the lower rates paid in other developed countries. Administration officials argue Americans have spent years subsidizing cheaper medicine overseas while paying the highest prices in the world for many common prescriptions.

The proposal would mainly affect drugs purchased through Medicare and Medicaid programs. The administration also projected more than $64 billion in Medicaid savings during the next decade. Officials said negotiations with drug manufacturers are ongoing and described the current agreements as a tentative plan rather than a finalized nationwide pricing system.

Democrats in Congress immediately challenged the announcement, arguing that the administration released few concrete details about how the savings estimates were calculated. Some healthcare economists also questioned whether pharmaceutical companies would simply offset losses by raising prices elsewhere in the system, including private insurance markets.

Why It Matters

Prescription drug costs remain one of the most politically sensitive healthcare issues in the country because they affect nearly every household in some form. Americans routinely pay several times more for medications than patients in Europe or Canada, even when the drugs are produced by the same manufacturers in the same facilities.

Why Apple’s latest move has #1 software company’s investors excited

Apple just enabled Starlink satellite support to T-Mobile iPhones.

One of the biggest potential winners from global satellite coverage?

Mode Mobile.

Just about everything Elon touches turns to gold:

• SpaceX projected IPO at $1.75T
• Tesla up by over 30,000% since IPO
• And now - iPhone’s get satellite access

But while Wall Street focuses on Apple, Mode Mobile is quietly positioned to capitalize on this global satellite revolution.

Their EarnPhone technology already:

• Reaches 490M+ users worldwide
• Helped those users save and earn over $1 billion
• Grew revenue 32,481%

And that was before global satellite coverage.

With SpaceX eliminating "dead zones," Mode's earning technology can reach 3B+ unbanked people globally in rural populations worldwide.

We’re talking about emerging markets with no infrastructure.

Right now, you can still invest at $0.50/share.

Over 59,000 shareholders have already claimed their shares and they’ve just secured the $MODE ticker from Nasdaq. The time to invest is now, before any potential IPO.*

Tap into a $1T opportunity — invest now at just $0.50/share and get up to 20% bonus!

For years, both Republican and Democratic administrations talked about confronting pharmaceutical pricing practices, but major structural changes have been difficult to implement. Drug companies have some of the strongest lobbying operations in Washington, and the industry counters that high revenues help fund medical research and future treatments.

This effort is notable because it’s coming from a Republican administration that has traditionally opposed heavy government involvement in private markets. The Trump administration believes the plan is a good alternative to direct price controls, hoping it will correct international pricing disparities that have long disadvantaged American consumers.

There is still uncertainty about how much consumers would actually notice at the pharmacy counter. Drug pricing is layered through insurers, pharmacy benefit managers, manufacturers, and government programs. Even if wholesale prices fall, savings do not always move cleanly through the system to individual patients.

How It Affects You

If the administration’s projections are accurate, some Medicare and Medicaid recipients will eventually see far lower out-of-pocket costs for expensive prescriptions. For seniors managing chronic conditions like diabetes, heart disease, or arthritis, this could be a big money saver, as monthly medication costs can easily reach hundreds of dollars.

Americans with employer-sponsored insurance may take a bit longer to notice any differences, as private insurance pricing is negotiated separately, and insurers often lock in contracts years in advance. Even if federal programs secure lower rates, there is no guarantee that private plans will automatically follow suit.

*Disclaimer: Please read the offering circular and related risks at invest.modemobile.com. This is a paid advertisement for Mode Mobile’s Regulation A+ Offering.

Mode Mobile recently received their ticker reservation with Nasdaq ($MODE), indicating an intent to IPO in the next 24 months. An intent to IPO is no guarantee that an actual IPO will occur.

The Deloitte rankings are based on submitted applications and public company database research, with winners selected based on their fiscal-year revenue growth percentage over a three-year period.

Tesla return calculated based on Yahoo Finance adjusted stock price data from June 29, 2010 to January 31, 2025.